High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii

References

• Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38: 1449–59
   PubMed Web of Science ®Google Scholar
• Garcia-Garmedia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Peres-Paredes C, Barrero-Almodovar AE, et al. Risk factors for Acinetobacter baumannii nosocomial bacteraemia in critically ill patients: a cohort study. Clin Infect Dis 2001; 33: 939–46
   PubMed Web of Science ®Google Scholar
• Go E.s, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344: 1329–32
   PubMed Web of Science ®Google Scholar
• Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002; 8: 144–53
   PubMed Web of Science ®Google Scholar
• Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemotherapy 1998; 42: 793–802
   PubMed Web of Science ®Google Scholar
• Murray CK, Hospenthal DR. Treatment of multidrug-resistant Acinetobacter. Curr Opin Infect Dis 2005; 18: 502–5
   PubMed Web of Science ®Google Scholar
• Koulenti D, Rello J. Gram-negative bacterial pneumonia: aetiology and management. Curr Opin Pulm Med 2006; 12: 198–204
   PubMed Web of Science ®Google Scholar
• Chastre J. Conference Summary: Ventilator-associated pneumonia. Respiratory Care 2005; 50: 975–83
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standard for antimicrobial disk susceptibility testing; 15th informational supplement 2005;M100–S15, Vol 25.
   Google Scholar
• Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med 2003; 29: 2072–6
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111–8
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampicin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40: 117–20
   PubMed Web of Science ®Google Scholar
• Lee Cm, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Inf Dis 2005; 37: 195–9
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kassiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333–41
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Kassiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infectious Diseases 2005; 24: 1–7
   Web of Science ®Google Scholar
• Rontriguez-Hernandez MJ, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jimenez-Mejias ME, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemotherapy 2001; 47: 479–82
   PubMed Web of Science ®Google Scholar
• Valcke YJ, Rosseel MT, Pauwels RA, Bogaert MG, Van der Straeten ME. Penetration of ampicillin and sulbactam in the lower airways during respiratory infections. Antimicrob Agents Chemother 1990; 34: 958–62
   PubMed Web of Science ®Google Scholar
• Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis 1986; 8(Suppl 5)S503–11
   PubMedGoogle Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationales for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–12
   PubMed Web of Science ®Google Scholar
• Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol 2004; 42: 5102–8
   PubMed Web of Science ®Google Scholar
• CDC. www.cdc.gov/drspsurveillancetoolkit/docs/laboratorymethods.pdf.
   Google Scholar
• Higgins PG, Wisplihgoff H, Stefanic D, Seifert H. In vitro activities of the b-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with b-lactams against epidemiologically characterized multidrug- resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004; 48: 1586–92
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34: 1424–30
   Web of Science ®Google Scholar
• Allen DM, Hartman BJ. Acinetobacter species. Principles and Practice of Infectious Disease5th edn, JL Mandell, JE Bennett, R Dolin. Churchill Livingstone, New York 2000; 2339–42
   Google Scholar
• Reina, R, Estenssoro, E, Saenz, G, Canales, HS, Gonzalvo, R, Vidal, G, , et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058–65.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31: 649–55
   PubMed Web of Science ®Google Scholar
• Choi JY, Kim Co, Park YS, Yoon HJ, Shin SY, Kim YK, et al. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteraemia. Yonsei Med J 2006; 47: 63–9
   PubMed Web of Science ®Google Scholar